share_log

T2 Biosystems | 8-K: Disclosure Information of Public Offering in Compliance With Nasdaq Listing Rule 5550(b)(2)

T2 Biosystems | 8-K: Disclosure Information of Public Offering in Compliance With Nasdaq Listing Rule 5550(b)(2)

T2 Biosystems | 8-K:为符合纳斯达克上市规则5550(b)(2)最低股东权益规定相关信息披露
美股sec公告 ·  05/23 04:56
牛牛AI助手已提取核心信息
T2 Biosystems, a medical diagnostic company, has successfully regained compliance with the Nasdaq's market value of listed securities (MVLS) requirement for continued listing on the Nasdaq Capital Market. This development comes after the company was previously notified by Nasdaq on November 22, 2023, of its non-compliance due to its failure to maintain the minimum required MVLS of $35 million over a 30-day period. T2 Biosystems appealed for an exception and was granted until May 20, 2024, to demonstrate compliance. The company's successful compliance has been confirmed by Nasdaq on May 21, 2024. However, T2 Biosystems will be under a Mandatory Panel Monitor for one year, during which any failure to meet continued listing requirements could lead to delisting without additional time to regain compliance, although the company retains the right to request a new hearing before any delisting action is taken.
T2 Biosystems, a medical diagnostic company, has successfully regained compliance with the Nasdaq's market value of listed securities (MVLS) requirement for continued listing on the Nasdaq Capital Market. This development comes after the company was previously notified by Nasdaq on November 22, 2023, of its non-compliance due to its failure to maintain the minimum required MVLS of $35 million over a 30-day period. T2 Biosystems appealed for an exception and was granted until May 20, 2024, to demonstrate compliance. The company's successful compliance has been confirmed by Nasdaq on May 21, 2024. However, T2 Biosystems will be under a Mandatory Panel Monitor for one year, during which any failure to meet continued listing requirements could lead to delisting without additional time to regain compliance, although the company retains the right to request a new hearing before any delisting action is taken.
医疗诊断公司T2 Biosystems成功恢复了纳斯达克上市证券市值(MVLS)要求继续在纳斯达克资本市场上市的要求。这一事态发展是在纳斯达克此前于2023年11月22日通知该公司因未能在30天内维持3500万美元的最低MVLS而违规行为之后发生的。T2 Biosystems提出例外申请,并获准在2024年5月20日之前获得批准,以证明其合规性。该公司的成功合规性已于2024年5月21日得到纳斯达克的确认。但是,T2 Biosystems将接受为期一年的强制性小组监督,在此期间,任何未能满足持续上市要求的行为都可能导致在没有更多时间恢复合规的情况下退市,尽管该公司保留在采取任何退市行动之前要求举行新的听证会的权利。
医疗诊断公司T2 Biosystems成功恢复了纳斯达克上市证券市值(MVLS)要求继续在纳斯达克资本市场上市的要求。这一事态发展是在纳斯达克此前于2023年11月22日通知该公司因未能在30天内维持3500万美元的最低MVLS而违规行为之后发生的。T2 Biosystems提出例外申请,并获准在2024年5月20日之前获得批准,以证明其合规性。该公司的成功合规性已于2024年5月21日得到纳斯达克的确认。但是,T2 Biosystems将接受为期一年的强制性小组监督,在此期间,任何未能满足持续上市要求的行为都可能导致在没有更多时间恢复合规的情况下退市,尽管该公司保留在采取任何退市行动之前要求举行新的听证会的权利。

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成,只对中国内地以外的地区提供。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。